News

The mean daily alcohol consumption was also lower in the psilocybin group compared to the placebo group.

A lower SPPB score was associated with greater risk of composite and individual CVD outcomes.

Olipudase alfa (Xenpozyme) was developed by Sanofi to treat symptoms unrelated to the central nervous system in pediatric and adult patients with the life-threatening condition.

Recent research from George Washington University analyzed the effects of COVID-19 on recruitment and funding for medical school pathway programs.

The FDA granted priority review for the Bioloigics License Application (BLA) Sanofi submitted for efanesoctocog alfa indicated for individuals with hemophilia A with a decision date set for February 28, 2023.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 5 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder diagnosis.

In the study, 60.4% achieved resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months.

The results show 88.6% of participants had medium to high range emotion exhaustion, while 82.8% exhibited medium to high range depersonalization and 19.6% of patients had low to medium range personal accomplishment.

Patients with Parkinson disease had more pronounced sleep instability than those with other disorders marked by alpha-synuclein buildup, but those differences diminished after adjusting for medication differences, a new study found.

Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19.

An Oakland-based analysis of mortality among homeless adults aged ≥50 years old illuminates the need for more proactive homeless care policies.

Digital screening more than doubled the detection rate of treatment-relevant AF in both phases of eBRAVE-AF trial.

Pemigatinib (Pemazyre) becomes the first and only targeted treatment for adults with extremely rare and aggressive blood cancer.

A recent study developed framework to improve fall prevention methodology across the country’s primary health care system.

For liver-related deaths, 90% were from liver cancer, while the most common cause of non-liver-related deaths was malignancy.

Reductions in prescribed benzodiazepines were especially noted in continuing prescriptions.

The cohort study is the first to report developmental cascades between disturbed sleep and depressive symptoms throughout childhood and early adolescence.

Research on the links between AMD and sleep dysfunction is limited but suggests a bidirectional relationship, a systematic review found.

Targeting a mean arterial blood pressure of 77 mm Hg or 63 mm Hg was not associated with significantly different percentages of patients dying or having severe disability or coma.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.

Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.

Clinical remission at week 4 and the steroid dose reduction rate at week 4 were linked to medication discontinuation within 12 weeks.

Treatment adherence remains a concern in psychiatry.

Severity of disease in patients with PAH coincided with cfDNA concentrations according to an NIH study with data from 2 independent cohorts.

The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.

The risk of coronary heart disease and stroke decreased by 22% for every 1 point rise in the sleep score at baseline.

Nonsegmental vitiligo not only affects the skin but can destroy melanocytes in other areas of the body including the eye, new research shows.